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Additional file 1. Unadjusted and adjusted hazard ratios of virologic failure (n= 1 
6264). 2 
 3 
 Univariate analysis Multivariate analysis 
PHA (p=0.493), VIF*** (1.01-1.16) 
 cHR* 95% CI p aHR** 95% CI p 
VL group       
6 months 1  0.257 1  0.016 
3 months 1.10 0.93-1.29  0.78 0.64-0.95  
Sex       
Female 1  0.058 1  0.767 
Male 0.84 0.70-1.01  0.97 0.80-1.18  
Age
1
 0.71 0.63-0.79 <0.001 0.72 0.64-0.81 <0.001 
CD4 count
2 0.90 0.85-0.95 <0.001 0.91 0.85-0.96 0.001 
WHO 
stage 
      
I + II 1  0.001 1  0.001 
III + IV 1.50 1.19-1.89  1.57 1.21-2.03  
Clinic       
I 1  0.28 1  0.437 
II 0.96 0.78-1.19  0.92 0.73-1.14  
III 1.12 0.93-1.34  1.08 0.90-1.30  
Baseline 
NNRTI 
      
Nevirapine 1  0.004 1  <0.001 




      




* cHR, crude hazard ratio  5 
** aHR, adjusted hazard ratio 6 
*** PHA, p value for the global proportional-hazards assumption; VIF, range of 7 
variance inflation factors 8 
1
 per 10 years 9 
2
 per 50 cells/μl 10 
3
 Calendar time of ART initiation; per 90 days 11 
